Cerveau Technologies announced a research collaboration with Banner Health to support various research projects studying the stages of Alzheimer’s disease and other neurodegenerative diseases. These research projects will utilize an investigational imaging agent (MK-6240) to be used in positron emission tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
“We are delighted to be working with Cerveau to advance the study of Alzheimer’s using their promising tau PET tracer,” said Eric Reiman, MD, executive director at Banner Alzheimer’s Institute and CEO of Banner Research. “Amyloid, tau and other biomarkers will play increasingly important roles in the understanding of and fight against this terrible disease.”
As part of the agreement, Cerveau will support various research projects and transfer to Banner Health the technology for production of [18F]MK- 6240 needed for the initiatives.
“Cerveau is excited to be working with Dr. Reiman and his colleagues to better understand tau pathology,” said Rick Hiatt, President of Cerveau Technologies, Inc., “The partnership with Banner Health is another important step forward in our strategy of developing an international network of key collaborators and production sites to enable broad access for scientific research and clinical trial support.”
